X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare with Dishman Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs DISHMAN PHARMA - Comparison Results

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES DISHMAN PHARMA ALKEM LABORATORIES/
DISHMAN PHARMA
 
P/E (TTM) x - 25.1 - View Chart
P/BV x 7.8 3.3 231.8% View Chart
Dividend Yield % 0.6 0.7 84.1%  

Financials

 ALKEM LABORATORIES   DISHMAN PHARMA
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
DISHMAN PHARMA
Mar-16
ALKEM LABORATORIES/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,589374 424.4%   
Low Rs1,232129 955.8%   
Sales per share (Unadj.) Rs417.5197.8 211.1%  
Earnings per share (Unadj.) Rs56.321.2 265.5%  
Cash flow per share (Unadj.) Rs64.734.7 186.4%  
Dividends per share (Unadj.) Rs12.702.00 635.0%  
Dividend yield (eoy) %0.90.8 113.3%  
Book value per share (Unadj.) Rs292.9179.9 162.8%  
Shares outstanding (eoy) m119.5780.69 148.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.41.3 265.6%   
Avg P/E ratio x25.111.9 211.1%  
P/CF ratio (eoy) x21.87.2 300.8%  
Price / Book Value ratio x4.81.4 344.2%  
Dividend payout %22.69.4 239.2%   
Avg Mkt Cap Rs m168,65320,306 830.6%   
No. of employees `000NA0.8 0.0%   
Total wages/salary Rs m9,1715,355 171.3%   
Avg. sales/employee Rs ThNM19,252.7-  
Avg. wages/employee Rs ThNM6,459.5-  
Avg. net profit/employee Rs ThNM2,064.1-  
INCOME DATA
Net Sales Rs m49,91515,961 312.7%  
Other income Rs m1,645265 619.9%   
Total revenues Rs m51,56116,226 317.8%   
Gross profit Rs m8,4824,103 206.7%  
Depreciation Rs m1,0061,091 92.2%   
Interest Rs m671944 71.0%   
Profit before tax Rs m8,4512,334 362.1%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,606624 257.5%   
Profit after tax Rs m6,7311,711 393.4%  
Gross profit margin %17.025.7 66.1%  
Effective tax rate %19.026.7 71.1%   
Net profit margin %13.510.7 125.8%  
BALANCE SHEET DATA
Current assets Rs m27,06211,018 245.6%   
Current liabilities Rs m15,3249,517 161.0%   
Net working cap to sales %23.59.4 250.1%  
Current ratio x1.81.2 152.5%  
Inventory Days Days67110 60.2%  
Debtors Days Days4135 118.5%  
Net fixed assets Rs m12,61016,304 77.3%   
Share capital Rs m239161 148.1%   
"Free" reserves Rs m34,49012,907 267.2%   
Net worth Rs m35,02714,516 241.3%   
Long term debt Rs m1,2124,189 28.9%   
Total assets Rs m54,38729,805 182.5%  
Interest coverage x13.63.5 391.9%   
Debt to equity ratio x00.3 12.0%  
Sales to assets ratio x0.90.5 171.4%   
Return on assets %13.68.9 152.8%  
Return on equity %19.211.8 163.0%  
Return on capital %24.917.5 141.8%  
Exports to sales %12.924.8 52.2%   
Imports to sales %3.13.7 82.6%   
Exports (fob) Rs m6,4613,956 163.3%   
Imports (cif) Rs m1,540596 258.3%   
Fx inflow Rs m6,5634,952 132.6%   
Fx outflow Rs m3,012697 432.2%   
Net fx Rs m3,5524,255 83.5%   
CASH FLOW
From Operations Rs m7,2592,786 260.5%  
From Investments Rs m1,864-1,529 -121.9%  
From Financial Activity Rs m-9,273-941 985.3%  
Net Cashflow Rs m-150316 -47.4%  

Share Holding

Indian Promoters % 66.9 61.4 109.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 33.1 3.7 894.6%  
FIIs % 0.0 12.7 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 22.1 -  
Shareholders   68,381 46,261 147.8%  
Pledged promoter(s) holding % 0.0 35.8 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   VENUS REMEDIES  ORCHID PHARMA LTD  SANOFI INDIA  J.B.CHEMICALS  SHASUN PHARMA  

Compare ALKEM LABORATORIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day in Red; Realty Stocks Top Losers(Closing)

After opening the day in green, share markets in India witnessed volatile trading activity throughout the day and ended the day on a dull note.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Is it Wise to Ignore Bitcoins?(The 5 Minute Wrapup)

Jan 4, 2018

While investing in bitcoins, it would make sense to treat it as another asset class and decide accordingly.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Jan 16, 2018 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES - DIVIS LABORATORIES COMPARISON

COMPARE ALKEM LABORATORIES WITH

MARKET STATS